Develops biologics for autoimmune diseases and cancer immunotherapy, focusing on targeting immune checkpoints.
Q32 Bio Inc., a clinical-stage biotechnology firm based in Waltham, Massachusetts, specializes in developing biologic therapeutics aimed at restoring healthy immune balance for patients grappling with autoimmune and inflammatory diseases driven by dysfunctional immune responses in the United States.
At the forefront of its innovative pipeline is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein designed to restore complement regulation. This promising candidate has successfully completed Phase I clinical trials targeting renal and other complement-mediated diseases, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
In addition to ADX-097, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody that antagonizes the interleukin-7 receptor alpha. This novel therapy is currently in Phase II clinical trials for treating atopic dermatitis and alopecia areata, focusing on re-regulating adaptive immune responses by blocking interleukin-7 and thymic stromal lymphopoietin signaling pathways. Formerly known as AdMIRx Inc., Q32 Bio rebranded in April 2020 to reflect its expanded mission and dedication to pioneering transformative treatments in the biopharmaceutical landscape.